Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | anti-GPC3-IL15-iC9-expressing CAR T-cells |
Synonyms | |
Therapy Description |
anti-GPC3-IL15-iC9-expressing CAR T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting GPC3, and co-express IL15 and inducible caspase 9 (iC9), which potentially induce antitumor activity (PMID: 39604730). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
anti-GPC3-IL15-iC9-expressing CAR T-cells | CATCH T-cells|AGAR T-cells | anti-GPC3-IL15-iC9-expressing CAR T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting GPC3, and co-express IL15 and inducible caspase 9 (iC9), which potentially induce antitumor activity (PMID: 39604730). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06815432 | Phase I | anti-GPC3-IL15-iC9-expressing CAR T-cells | GPC-3 CAR T CELLS for Recurrent GPC-3 Positive Glioblastoma | Not yet recruiting | USA | 0 |
NCT04377932 | Phase I | Cyclophosphamide + Fludarabine anti-GPC3-IL15-iC9-expressing CAR T-cells | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Recruiting | USA | 0 |